{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:42:56Z","timestamp":1783993376641,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Satsuma Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenital malformations (MCM), and spontaneous abortions (SA) associated with gestational use of DHE or triptans. Three cohort and one nested-case\u2013control analyses were conducted within the\u00a0Quebec Pregnancy Cohort to assess the risk of prematurity, LBW, MCM, and SA. Exposure was defined dichotomously as use of\u00a0DHE or triptan during pregnancy. Generalized estimation equations were built to quantify the associations, adjusting for potential confounders. 233,900 eligible pregnancies were included in the analyses on prematurity, LBW, and MCM; 29,104 cases of SA were identified. Seventy-eight subjects (0.03%) were exposed to DHE and 526 (0.22%) to triptans. Adjusting for potential confounders, DHE and triptans were associated with increased risks of prematurity, LBW, MCM, and SA but not all estimates were statistically significant. DHE was associated with the risk of prematurity (aRR: 4.12, 95% CI 1.21\u201313.99); triptans were associated with the risk of SA (aOR: 1.63, 95% CI 1.34\u20131.98). After considering maternal migraine, all antimigraine specific medications increased the risk of some adverse pregnancy outcomes, but estimates were unstable.<\/jats:p>","DOI":"10.1038\/s41598-021-97092-y","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T10:21:04Z","timestamp":1632910864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes"],"prefix":"10.1038","volume":"11","author":[{"given":"Anick","family":"B\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Kori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"97092_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton, R. B. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68, 343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21 (2007).","journal-title":"Neurology"},{"key":"97092_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejogrb.2006.08.025","volume":"134","author":"F Banhidy","year":"2007","unstructured":"Banhidy, F., Acs, N., Horvath-Puho, E. & Czeizel, A. E. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur. J. Obstet Gynecol. Reprod. Biol. 134, 157\u2013163. https:\/\/doi.org\/10.1016\/j.ejogrb.2006.08.025 (2007).","journal-title":"Eur. J. Obstet Gynecol. Reprod. Biol."},{"key":"97092_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12884-017-1399-0","volume":"17","author":"GE Harris","year":"2017","unstructured":"Harris, G. E., Wood, M., Eberhard-Gran, M., Lundqvist, C. & Nordeng, H. Patterns and predictors of analgesic use in pregnancy: A longitudinal drug utilization study with special focus on women with migraine. BMC Pregnancy Childbirth 17, 224. https:\/\/doi.org\/10.1186\/s12884-017-1399-0 (2017).","journal-title":"BMC Pregnancy Childbirth"},{"key":"97092_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/j.1468-2982.2009.01869.x","volume":"29","author":"K Nezvalova-Henriksen","year":"2009","unstructured":"Nezvalova-Henriksen, K., Spigset, O. & Nordeng, H. Maternal characteristics and migraine pharmacotherapy during pregnancy: Cross-sectional analysis of data from a large cohort study. Cephalalgia 29, 1267\u20131276. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01869.x (2009).","journal-title":"Cephalalgia"},{"key":"97092_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1212\/01.wnl.0000042477.63516.b2","volume":"60","author":"SD Silberstein","year":"2003","unstructured":"Silberstein, S. D., Young, W. B., Mendizabal, J. E., Rothrock, J. F. & Alam, A. S. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial. Neurology 60, 315\u2013321. https:\/\/doi.org\/10.1212\/01.wnl.0000042477.63516.b2 (2003).","journal-title":"Neurology"},{"key":"97092_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1526-4610.2012.02124.x","volume":"52","author":"C Dahlof","year":"2012","unstructured":"Dahlof, C. & Maassen Van Den Brink, A. Dihydroergotamine, ergotamine, methysergide and sumatriptan\u2014basic science in relation to migraine treatment. Headache 52, 707\u2013714. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02124.x (2012).","journal-title":"Headache"},{"key":"97092_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1211\/0022357991772321","volume":"51","author":"HH Pertz","year":"1999","unstructured":"Pertz, H. H., Brown, A. M., Gager, T. L. & Kaumann, A. J. Simple O-acylated derivatives of lysergol and dihydrolysergol-I: Synthesis and interaction with 5-HT2A, 5-HT2C and 5-HT1B receptors, and alpha1 adrenergic receptors. J. Pharm. Pharmacol. 51, 319\u2013330. https:\/\/doi.org\/10.1211\/0022357991772321 (1999).","journal-title":"J. Pharm. Pharmacol."},{"key":"97092_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1526-4610.2012.02172.x","volume":"52","author":"A Berard","year":"2012","unstructured":"Berard, A. & Kori, S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache 52, 1085\u20131093. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02172.x (2012).","journal-title":"Headache"},{"key":"97092_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1526-4610.2000.00003.x","volume":"40","author":"C Olesen","year":"2000","unstructured":"Olesen, C., Steffensen, F. H., Sorensen, H. T., Nielsen, G. L. & Olsen, J. Pregnancy outcome following prescription for sumatriptan. Headache 40, 20\u201324. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00003.x (2000).","journal-title":"Headache"},{"key":"97092_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrneurol.2015.29","volume":"11","author":"S Amundsen","year":"2015","unstructured":"Amundsen, S., Nordeng, H., Nezvalova-Henriksen, K., Stovner, L. J. & Spigset, O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat. Rev. Neurol. 11, 209\u2013219. https:\/\/doi.org\/10.1038\/nrneurol.2015.29 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"97092_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/practneurol-2019-002332","volume":"20","author":"SK Afridi","year":"2020","unstructured":"Afridi, S. K. Migraine: navigating the hormonal minefield. Pract Neurol 20, 115\u2013121. https:\/\/doi.org\/10.1136\/practneurol-2019-002332 (2020).","journal-title":"Pract Neurol"},{"key":"97092_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1753495X18769170","volume":"11","author":"SK Afridi","year":"2018","unstructured":"Afridi, S. K. Current concepts in migraine and their relevance to pregnancy. Obstet Med. 11, 154\u2013159. https:\/\/doi.org\/10.1177\/1753495X18769170 (2018).","journal-title":"Obstet Med."},{"key":"97092_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10534-5","author":"DC Dudman","year":"2021","unstructured":"Dudman, D. C. et al. A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: A contribution from the IMI2 ConcePTION project. J. Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10534-5 (2021).","journal-title":"J. Neurol."},{"key":"97092_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1177\/0333102417724152","volume":"38","author":"K Spielmann","year":"2018","unstructured":"Spielmann, K., Kayser, A., Beck, E., Meister, R. & Schaefer, C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 38, 1081\u20131092. https:\/\/doi.org\/10.1177\/0333102417724152 (2018).","journal-title":"Cephalalgia"},{"key":"97092_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/head.12500","volume":"55","author":"A Marchenko","year":"2015","unstructured":"Marchenko, A. et al. Pregnancy outcome following prenatal exposure to triptan medications: A meta-analysis. Headache 55, 490\u2013501. https:\/\/doi.org\/10.1111\/head.12500 (2015).","journal-title":"Headache"},{"key":"97092_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1468-2982.2009.01935.x","volume":"30","author":"HM Chen","year":"2010","unstructured":"Chen, H. M., Chen, S. F., Chen, Y. H. & Lin, H. C. Increased risk of adverse pregnancy outcomes for women with migraines: A nationwide population-based study. Cephalalgia 30, 433\u2013438. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01935.x (2010).","journal-title":"Cephalalgia"},{"key":"97092_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/head.13023","volume":"57","author":"TB Grossman","year":"2017","unstructured":"Grossman, T. B., Robbins, M. S., Govindappagari, S. & Dayal, A. K. Delivery outcomes of patients with acute migraine in pregnancy: A retrospective study. Headache 57, 605\u2013611. https:\/\/doi.org\/10.1111\/head.13023 (2017).","journal-title":"Headache"},{"key":"97092_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/OGX.0000000000000738","volume":"74","author":"AM Aukes","year":"2019","unstructured":"Aukes, A. M., Yurtsever, F. N., Boutin, A., Visser, M. C. & de Groot, C. J. M. Associations between migraine and adverse pregnancy outcomes: Systematic review and meta-analysis. Obstet Gynecol. Surv. 74, 738\u2013748. https:\/\/doi.org\/10.1097\/OGX.0000000000000738 (2019).","journal-title":"Obstet Gynecol. Surv."},{"key":"97092_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1365-2125.2007.02901.x","volume":"64","author":"F Banhidy","year":"2007","unstructured":"Banhidy, F., Acs, N., Puho, E. & Czeizel, A. E. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br. J. Clin. Pharmacol. 64, 510\u2013516. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02901.x (2007).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"97092_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5694\/j.1326-5377.1978.tb77379.x","volume":"2","author":"B Berde","year":"1978","unstructured":"Berde, B. Pharmacology of ergot alkaloids in clinical use. Med. J. Aust. 2, 3\u201313 (1978).","journal-title":"Med. J. Aust."},{"key":"97092_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11590370-000000000-00000","volume":"34","author":"B Kallen","year":"2011","unstructured":"Kallen, B., Nilsson, E. & Otterblad Olausson, P. Delivery outcome after maternal use of drugs for migraine: A register study in Sweden. Drug. Saf. 34, 691\u2013703. https:\/\/doi.org\/10.2165\/11590370-000000000-00000 (2011).","journal-title":"Drug. Saf."},{"key":"97092_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s0002-9378(16)38739-7","volume":"64","author":"SG Altman","year":"1952","unstructured":"Altman, S. G., Waltman, R., Lubin, S. & Reynolds, S. R. Oxytocic and toxic actions of dihydroergotamine-45. Am. J. Obstet. Gynecol. 64, 101\u2013109. https:\/\/doi.org\/10.1016\/s0002-9378(16)38739-7 (1952).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"97092_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00228-016-2127-9","volume":"72","author":"S Amundsen","year":"2016","unstructured":"Amundsen, S., Ovrebo, T. G., Amble, N. M., Poole, A. C. & Nordeng, H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: A cross-sectional study among 401 Norwegian women. Eur. J. Clin. Pharmacol. 72, 1525\u20131535. https:\/\/doi.org\/10.1007\/s00228-016-2127-9 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"97092_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/bdra.23604","volume":"109","author":"JP Zhao","year":"2017","unstructured":"Zhao, J. P., Sheehy, O., Gorgui, J. & Berard, A. Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy?. Birth Defects Res. 109, 423\u2013431. https:\/\/doi.org\/10.1002\/bdra.23604 (2017).","journal-title":"Birth Defects Res."},{"key":"97092_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0895-4356(90)90060-3","volume":"43","author":"SS Coughlin","year":"1990","unstructured":"Coughlin, S. S. Recall bias in epidemiologic studies. J. Clin. Epidemiol. 43, 87\u201391. https:\/\/doi.org\/10.1016\/0895-4356(90)90060-3 (1990).","journal-title":"J. Clin. Epidemiol."},{"key":"97092_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40264-015-0302-z","volume":"38","author":"L de Jonge","year":"2015","unstructured":"de Jonge, L., de Walle, H. E., de Jong-van den Berg, L. T., van Langen, I. M. & Bakker, M. K. Actual use of medications prescribed during pregnancy: A cross-sectional study using data from a population-based congenital anomaly registry. Drug. Saf. 38, 737\u2013747. https:\/\/doi.org\/10.1007\/s40264-015-0302-z (2015).","journal-title":"Drug. Saf."},{"key":"97092_CR27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/pds.3446","volume":"22","author":"L Blais","year":"2013","unstructured":"Blais, L., Berard, A., Kettani, F. Z. & Forget, A. Validity of congenital malformation diagnostic codes recorded in Quebec\u2019s administrative databases. Pharmacoepidemiol. Drug. Saf. 22, 881\u2013889. https:\/\/doi.org\/10.1002\/pds.3446 (2013).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"97092_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/pds.1558","volume":"17","author":"A Vilain","year":"2008","unstructured":"Vilain, A., Otis, S., Forget, A. & Blais, L. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol. Drug. Saf. 17, 345\u2013353. https:\/\/doi.org\/10.1002\/pds.1558 (2008).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"97092_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1503\/cmaj.110454","volume":"183","author":"HR Nakhai-Pour","year":"2011","unstructured":"Nakhai-Pour, H. R., Broy, P., Sheehy, O. & Berard, A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 183, 1713\u20131720. https:\/\/doi.org\/10.1503\/cmaj.110454 (2011).","journal-title":"CMAJ"},{"key":"97092_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/bmj.327.7411.368","volume":"327","author":"DK Li","year":"2003","unstructured":"Li, D. K., Liu, L. & Odouli, R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: Population based cohort study. BMJ 327, 368. https:\/\/doi.org\/10.1136\/bmj.327.7411.368 (2003).","journal-title":"BMJ"},{"issue":"2","key":"97092_CR31","first-page":"156","volume":"18","author":"A B\u00e9rard","year":"2009","unstructured":"B\u00e9rard, A., Kulaga, S. & Nakhai-Pour, H. R. Magnitude of confounding caused by missing information in the studies on adverse pregnancy outcomes. Pharmacoepidemiol. Drug. Saf. 18(2), 156 (2009).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"97092_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1526-4610.2010.01619.x","volume":"50","author":"K Nezvalova-Henriksen","year":"2010","unstructured":"Nezvalova-Henriksen, K., Spigset, O. & Nordeng, H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: Results from the Norwegian Mother and Child Cohort Study. Headache 50, 563\u2013575. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01619.x (2010).","journal-title":"Headache"},{"key":"97092_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/s1701-2163(15)30230-9","volume":"37","author":"RD Wilson","year":"2015","unstructured":"Wilson, R. D. et al. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J. Obstet. Gynaecol. Can. 37, 534\u2013552. https:\/\/doi.org\/10.1016\/s1701-2163(15)30230-9 (2015).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"97092_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pedneo.2014.10.002","volume":"56","author":"AC Egbe","year":"2015","unstructured":"Egbe, A. C. Birth defects in the newborn population: Race and ethnicity. Pediatr. Neonatol. 56, 183\u2013188. https:\/\/doi.org\/10.1016\/j.pedneo.2014.10.002 (2015).","journal-title":"Pediatr. Neonatol."},{"key":"97092_CR35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1051\/medsci\/20072311997","volume":"23","author":"AM Laberge","year":"2007","unstructured":"Laberge, A. M. Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present. Med. Sci. (Paris) 23, 997\u20131001. https:\/\/doi.org\/10.1051\/medsci\/20072311997 (2007).","journal-title":"Med. Sci. (Paris)"},{"key":"97092_CR36","first-page":"e198","volume":"22","author":"JP Zhao","year":"2015","unstructured":"Zhao, J. P., Sheehy, O. & Berard, A. Regional variations in the prevalence of major congenital malformations in Quebec: The importance of fetal growth environment. J. Popul. Ther. Clin. Pharmacol. 22, e198-210 (2015).","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"97092_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093870","volume":"9","author":"A Berard","year":"2014","unstructured":"Berard, A. & Sheehy, O. The Quebec pregnancy cohort\u2013prevalence of medication use during gestation and pregnancy outcomes. PLoS ONE 9, e93870. https:\/\/doi.org\/10.1371\/journal.pone.0093870 (2014).","journal-title":"PLoS ONE"},{"key":"97092_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251746","volume":"16","author":"A Berard","year":"2021","unstructured":"Berard, A. et al. Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy. PLoS ONE 16, e0251746. https:\/\/doi.org\/10.1371\/journal.pone.0251746 (2021).","journal-title":"PLoS ONE"},{"key":"97092_CR39","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/kez405","volume":"59","author":"K Palmsten","year":"2020","unstructured":"Palmsten, K. et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford) 59, 1262\u20131271. https:\/\/doi.org\/10.1093\/rheumatology\/kez405 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"97092_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.2308","volume":"39","author":"P Wu","year":"2019","unstructured":"Wu, P. et al. Association between first trimester antidepressant use and risk of spontaneous abortion. Pharmacotherapy 39, 889\u2013898. https:\/\/doi.org\/10.1002\/phar.2308 (2019).","journal-title":"Pharmacotherapy"},{"key":"97092_CR41","first-page":"e360","volume":"16","author":"A Berard","year":"2009","unstructured":"Berard, A. & Lacasse, A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can. J. Clin. Pharmacol. 16, e360-369 (2009).","journal-title":"Can. J. Clin. Pharmacol."},{"key":"97092_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026690","volume":"9","author":"S Amundsen","year":"2019","unstructured":"Amundsen, S., Ovrebo, T. G., Amble, N. M. S., Poole, A. C. & Nordeng, H. Risk perception, beliefs about medicines and medical adherence among pregnant and breastfeeding women with migraine: findings from a cross-sectional study in Norway. BMJ Open 9, e026690. https:\/\/doi.org\/10.1136\/bmjopen-2018-026690 (2019).","journal-title":"BMJ Open"},{"key":"97092_CR43","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/j.1471-0528.2009.02377.x","volume":"116","author":"S Kulaga","year":"2009","unstructured":"Kulaga, S., Zargarzadeh, A. H. & Berard, A. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. BJOG 116, 1788\u20131795. https:\/\/doi.org\/10.1111\/j.1471-0528.2009.02377.x (2009).","journal-title":"BJOG"},{"key":"97092_CR44","unstructured":"Kenneth, J.R., Timothy, L.L., Sander, G. Modern Epidemiology. Publisher: Lippincott Williams & Wilkins, (2008) ISBN 10: 0781755646."},{"key":"97092_CR45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/s1701-2163(16)34177-9","volume":"31","author":"A Einarson","year":"2009","unstructured":"Einarson, A., Choi, J., Einarson, T. R. & Koren, G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J. Obstet. Gynaecol. Can. 31, 452\u2013456. https:\/\/doi.org\/10.1016\/s1701-2163(16)34177-9 (2009).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"97092_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0002-8703(03)00512-X","volume":"146","author":"V Essebag","year":"2003","unstructured":"Essebag, V., Genest, J. Jr., Suissa, S. & Pilote, L. The nested case-control study in cardiology. Am. Heart J. 146, 581\u2013590. https:\/\/doi.org\/10.1016\/S0002-8703(03)00512-X (2003).","journal-title":"Am. Heart J."},{"key":"97092_CR47","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1503\/cmaj.091208","volume":"182","author":"HR Nakhai-Pour","year":"2010","unstructured":"Nakhai-Pour, H. R., Broy, P. & Berard, A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182, 1031\u20131037. https:\/\/doi.org\/10.1503\/cmaj.091208 (2010).","journal-title":"CMAJ"},{"key":"97092_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/eth.12713","volume":"124","author":"S Pek\u00e1r","year":"2018","unstructured":"Pek\u00e1r, S. & Brabec, M. Generalized estimating equations: A pragmatic and flexible approach to the marginal GLM modelling of correlated data in the behavioural sciences. Ethology 124, 86\u201393 (2018).","journal-title":"Ethology"},{"key":"97092_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001148","author":"E Jimenez-Solem","year":"2012","unstructured":"Jimenez-Solem, E. et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2012-001148 (2012).","journal-title":"BMJ Open"},{"key":"97092_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: Introducing the e-value. Ann. Int. Med. 167, 268\u2013274. https:\/\/doi.org\/10.7326\/M16-2607 (2017).","journal-title":"Ann. Int. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97092-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97092-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97092-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:04:31Z","timestamp":1670083471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97092-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97092"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97092-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B\u00e9rard A and Zhao JP have no conflicts of interest to disclose. Strom S and Albrecht D are full time employees of Satsuma Pharmaceuticals. Kori S is an independent consultant hired by Satsuma Pharmaceuticals. This study was funded by Satsuma Pharmaceuticals Inc. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The principal author takes full responsibility for the data presented in this study, analysis of the data, conclusions, and conduct of the research. The principal author had full access to those data and has maintained the right to publish any and all data independent of any third party.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19302"}}